BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27680411)

  • 1. Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine-Enhanced Liver Magnetic Resonance.
    Chu LC; Pozzessere C; Corona-Villalobos CP; CastaƱos S; Rastegar N; Halappa V; Bonekamp S; Emurano E; Kamel IR
    J Comput Assist Tomogr; 2016; 40(6):856-862. PubMed ID: 27680411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.
    Dioguardi Burgio M; Picone D; Cabibbo G; Midiri M; Lagalla R; Brancatelli G
    Abdom Radiol (NY); 2016 Aug; 41(8):1546-54. PubMed ID: 27052455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular Carcinoma: Retrospective Evaluation of the Correlation Between Gadobenate Dimeglumine-Enhanced Magnetic Resonance Imaging and Pathologic Grade.
    Huang X; Xiao Z; Zhang Y; Lin N; Xiong M; Huang X; Chen Q; Cao D
    J Comput Assist Tomogr; 2018; 42(3):365-372. PubMed ID: 29369947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
    Choi SH; Lee JM; Yu NC; Suh KS; Jang JJ; Kim SH; Choi BI
    AJR Am J Roentgenol; 2008 Aug; 191(2):529-36. PubMed ID: 18647927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
    Allen BC; Ho LM; Jaffe TA; Miller CM; Mazurowski MA; Bashir MR
    AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
    Jeon TY; Kim SH; Lee WJ; Lim HK
    Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of increasing the flip angle during the hepatocyte phase of gadobenate dimeglumine-enhanced 1.5T MRI in cirrhotic patients with hepatocellular carcinoma.
    Lee EJ; Kim DJ; Cho ES; Kim KA
    J Magn Reson Imaging; 2016 Mar; 43(3):713-9. PubMed ID: 26290384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating the hepatobiliary phase of gadobenate dimeglumine-enhanced MRI in the diagnosis of hepatocellular carcinoma: increasing the sensitivity without compromising specificity.
    Cortis K; Liotta R; Miraglia R; Caruso S; Tuzzolino F; Luca A
    Acta Radiol; 2016 Aug; 57(8):923-31. PubMed ID: 26567965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
    Quaia E; Pizzolato R; De Paoli L; Angileri R; Ukmar M; Cova MA
    J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesions.
    Fu GL; Du Y; Zee CS; Yang HF; Li Y; Duan RG; Zeng NL; Xiao DM
    J Comput Assist Tomogr; 2012; 36(1):14-9. PubMed ID: 22261765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
    Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
    Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hepatocellular carcinoma by chemoembolization: evaluation with 3DFT MR imaging.
    Murakami T; Nakamura H; Tsuda K; Nakanishi K; Hori S; Tomoda K; Mitani T; Kozuka T; Monden M; Wakasa K
    AJR Am J Roentgenol; 1993 Feb; 160(2):295-9. PubMed ID: 8380948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of viable tumor cells in hepatocellular carcinoma following transcatheter arterial chemoembolization with iodized oil. Pathologic correlation with dynamic turbo-FLASH MR imaging with Gd-DTPA.
    Murakami T; Nakamura H; Hori S; Tomoda K; Mitani T; Nakanishi K; Hashimoto T; Tsuda K; Kozuka T; Monden M
    Acta Radiol; 1993 Jul; 34(4):399-403. PubMed ID: 8391291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions.
    Pirovano G; Vanzulli A; Marti-Bonmati L; Grazioli L; Manfredi R; Greco A; Holzknecht N; Daldrup-Link HE; Rummeny E; Hamm B; Arneson V; Imperatori L; Kirchin MA; Spinazzi A
    AJR Am J Roentgenol; 2000 Oct; 175(4):1111-20. PubMed ID: 11000175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of treatment response of chemoembolization in hepatocellular carcinoma with diffusion-weighted imaging on 3.0-T MR imaging.
    Sahin H; Harman M; Cinar C; Bozkaya H; Parildar M; Elmas N
    J Vasc Interv Radiol; 2012 Feb; 23(2):241-7. PubMed ID: 22019180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.
    Kamel IR; Bluemke DA; Eng J; Liapi E; Messersmith W; Reyes DK; Geschwind JF
    J Vasc Interv Radiol; 2006 Mar; 17(3):505-12. PubMed ID: 16567675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Contrast-Enhanced Ultrasound for Early Therapeutic Evaluation of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization.
    Watanabe Y; Ogawa M; Kumagawa M; Hirayama M; Miura T; Matsumoto N; Nakagawara H; Yamamoto T; Moriyama M
    J Ultrasound Med; 2020 Mar; 39(3):431-440. PubMed ID: 31436341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Image fusion with volume navigation of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) for post-interventional follow-up after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinomas (HCC): Preliminary results.
    Ross CJ; Rennert J; Schacherer D; Girlich C; Hoffstetter P; Heiss P; Jung W; Feuerbach S; Zorger N; Jung EM
    Clin Hemorheol Microcirc; 2010; 46(2-3):101-15. PubMed ID: 21135486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.